<div id="readability-page-1"><div>CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX Please replace the release issued December 29, 2025 with the following corrected version due to multiple revisions. The updated release reads: DYNAVAX INVESTOR ALERT: KAHN SWICK &amp; FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF DYNAVAX TECHNOLOGIES CORPORATION - DVAX Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed sale of Dynavax Technologies Corporation (NasdaqGS: DVAX) to Sanofi (NYSE: SNY). Under the terms of the proposed transaction, shareholders of Dynavax will receive $15.50 in cash for each share of Dynavax that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-dvax/ to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk4MTk0MTNyMg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk4MTk0MTNyMg"/> Kahn Swick &amp; Foti, LLC Lewis S. Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20251229819413/en/</div></div>

德納維制藥

Kahn Swick & Foti, LLC 正在調查 Dynavax Technologies Corporation (DVAX) 擬議出售給賽諾菲的事宜，股東將獲得每股 15.50 美元。該公司旨在評估這一價格的合理性以及導致此次出售的過程，質疑是否低估了該公司的價值。感興趣的各方可以聯繫 KSF 以獲取有關其在此事中的法律權利的更多信息

CORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAX

更正並替換德納維製藥投資者警報：Kahn Swick & Foti, LLC 正在調查德納維製藥公司擬議出售中的價格和流程是否充分 - DVAX